Central nervous system lymphoma – Diagnostics – Overview of Information and Clinical Research

Diagnosing central nervous system lymphoma requires careful evaluation and multiple tests. Because the symptoms of this rare cancer can resemble many other conditions affecting the brain, spinal cord, or eyes, doctors use a combination of physical examinations, imaging techniques, laboratory tests, and tissue analysis to confirm the diagnosis. Understanding when to seek medical help and what to expect during the diagnostic process can help patients and their families prepare for this important step in their cancer journey.

Introduction: When to Seek Diagnostic Testing

If you notice unusual symptoms affecting your brain, nervous system, or vision, it’s important to see a doctor for evaluation. Anyone experiencing persistent or worsening neurological symptoms should undergo diagnostic testing to determine the cause. The symptoms that might prompt your doctor to investigate for central nervous system lymphoma can be quite varied, depending on where in your central nervous system a tumor might be located.^[1]

You should seek medical attention if you develop symptoms such as persistent headaches combined with confusion, seizures that appear suddenly or become more frequent over several days or weeks, vision problems like blurriness or seeing double, weakness affecting your arms or legs, or changes in your mental state such as memory loss or difficulty speaking. Other concerning signs include unexplained nausea and vomiting, hearing loss, difficulty swallowing, or problems controlling when you urinate or have bowel movements.^[1]

People who have weakened immune systems face a higher risk of developing this cancer and should be particularly vigilant about neurological symptoms. This includes individuals living with HIV or AIDS, those who have received organ transplants and take immunosuppressant medications, and people with certain inherited immune disorders. If you fall into any of these categories and notice neurological changes, prompt evaluation is especially important.^[1]

The symptoms of CNS lymphoma can appear suddenly or develop gradually over time. Because these symptoms overlap with many other conditions, from infections to strokes to other types of brain tumors, thorough diagnostic testing is essential. Early diagnosis allows for earlier treatment, which may improve outcomes for patients with this aggressive form of cancer.^[3]

Classic Diagnostic Methods

Physical and Neurological Examinations

The diagnostic journey typically begins with a comprehensive physical examination. Your healthcare provider will take a detailed medical history, asking about your symptoms, when they started, how they have changed over time, and whether you have any risk factors for CNS lymphoma. They will also ask about your general health, previous medical conditions, medications you take, and whether you have a history of immune system problems.^[9]

A neurological examination is a crucial part of the diagnostic process. During this exam, your doctor checks how well your brain, spinal cord, and nerves are functioning. They assess your mental status, asking questions to evaluate your memory, concentration, and ability to think clearly. The exam also tests your coordination and ability to walk normally, checks the strength and sensation in your muscles, and evaluates how well your senses and reflexes work. This type of examination, sometimes called a neuro exam, helps identify which areas of your nervous system might be affected by disease.^[9]

If your symptoms suggest possible eye involvement, you will undergo specialized eye examinations. One important test is called a slit lamp exam, which allows the doctor to examine the structures at the front and back of your eye in detail. Your eye doctor may also perform an eye exam with dilated pupils, where special eye drops temporarily enlarge your pupils so the doctor can look through the lens and examine your retina and other internal eye structures. Because CNS lymphoma can start in the eye or spread there, these examinations are an important part of the diagnostic workup.^[9]

Imaging Studies

Imaging tests create pictures of the inside of your body and are essential for detecting CNS lymphoma. These tests help doctors see tumors, determine their location and size, and understand how they might be affecting surrounding tissues. Multiple types of imaging may be used during the diagnostic process.^[1]

Magnetic resonance imaging (MRI) is typically the most important imaging test for diagnosing CNS lymphoma. This test uses powerful magnets and radio waves to create detailed images of your brain and spinal cord. MRI is particularly good at showing soft tissues and can reveal tumors that might not be visible on other types of scans. The images can show the exact location of abnormal areas, their size, and whether there are multiple tumors present. Sometimes a contrast material is injected into your vein before or during the MRI to make tumors show up more clearly on the images.^[1]

Computed tomography (CT) scans use X-rays to create cross-sectional images of your body. While MRI is usually preferred for evaluating the brain and spinal cord, CT scans can be useful when MRI is not available or when a patient cannot undergo MRI for medical reasons. CT scans can show areas of abnormal tissue and help identify the location of tumors. In patients with weakened immune systems, CT scans may show a characteristic pattern called ring enhancement in about half of cases.^[13]

Positron emission tomography (PET) scans play an important role in ruling out systemic disease. This type of scan uses a small amount of radioactive material to look for cancer cells throughout the body. For someone suspected of having CNS lymphoma, a PET-CT scan of the chest, abdomen, and pelvis helps doctors determine whether lymphoma is present only in the central nervous system (primary CNS lymphoma) or whether it has spread from elsewhere in the body (secondary CNS lymphoma). A clear PET-CT scan showing no disease outside the nervous system can sometimes eliminate the need for additional testing such as bone marrow biopsy.^[13]

⚠️ Important

If you have been prescribed corticosteroids before imaging tests are complete, tell your doctor immediately. These medications can temporarily shrink lymphoma tumors, which might make the cancer appear less extensive on imaging studies or even cause tumors to disappear temporarily from scans. This can complicate accurate diagnosis and staging, potentially delaying appropriate treatment.

Tissue Diagnosis and Laboratory Tests

While imaging tests can strongly suggest the presence of CNS lymphoma, confirming the diagnosis requires examining actual tissue under a microscope. This is called histopathological confirmation, and it is absolutely necessary before treatment can begin. The tissue sample shows exactly what type of cells are present and confirms whether they are cancerous.^[11]

The most common way to obtain tissue is through a brain biopsy. During this procedure, a neurosurgeon removes a small sample of abnormal tissue from the brain. The biopsy is typically performed as a surgical procedure, and the tissue is then examined by a specialist called a neuropathologist. The pathologist looks at the cells under a microscope to determine whether lymphoma is present and, if so, what specific type it is. Almost all primary CNS lymphomas turn out to be a type called diffuse large B-cell lymphoma.^[12]^[13]

In some cases, the neurosurgeon may remove all or most of the tumor during surgery rather than just taking a small sample. However, complete surgical removal is not typically the goal for CNS lymphoma because these tumors often respond well to chemotherapy and radiation, and surgery does not improve outcomes compared to less invasive biopsy followed by medical treatment.^[12]

Cerebrospinal fluid (CSF) examination is another important diagnostic test. Cerebrospinal fluid is the clear liquid that surrounds your brain and spinal cord. To collect this fluid, doctors perform a procedure called a lumbar puncture or spinal tap. During this test, a thin needle is inserted between bones in your lower back to withdraw a small amount of fluid. The fluid is then analyzed in a laboratory to look for cancer cells, abnormal proteins, or other signs of disease. In one study of patients with primary CNS lymphoma, about 17 percent were found to have cancer cells in their cerebrospinal fluid.^[13]

Blood tests are routinely performed as part of the diagnostic workup. These tests check your overall health and can identify factors that might affect treatment decisions or prognosis. Common blood tests include a complete blood count to check your blood cells, tests of liver and kidney function, and measurement of substances like lactose dehydrogenase (LDH), which can be elevated in lymphoma. Blood tests can also check for HIV infection and other conditions that affect the immune system, since these are risk factors for CNS lymphoma.^[13]

Distinguishing CNS Lymphoma from Other Conditions

One of the challenges in diagnosing CNS lymphoma is that its symptoms and appearance on imaging scans can look similar to many other brain conditions. Doctors must carefully distinguish CNS lymphoma from other possibilities, a process called differential diagnosis. The clinical presentation of CNS lymphoma is often nonspecific, meaning the symptoms don’t point clearly to one particular diagnosis.^[11]

Conditions that may resemble CNS lymphoma include other types of brain tumors such as glioblastoma or metastatic cancer that has spread to the brain from elsewhere in the body. Infections of the brain, particularly in people with weakened immune systems, can also produce similar symptoms and imaging findings. Inflammatory conditions affecting the brain, strokes, and other neurological disorders may need to be ruled out. This is why obtaining tissue for examination is so important—it provides definitive proof of what condition is actually present.^[11]

Doctors also need to determine whether lymphoma started in the central nervous system (primary CNS lymphoma) or spread there from lymphoma elsewhere in the body (secondary CNS lymphoma). This distinction is crucial because the two conditions are treated differently. The extent-of-disease evaluation, including PET scans and bone marrow examination when needed, helps make this determination.^[12]

Diagnostic Testing for Clinical Trial Qualification

If you are considering participating in a clinical trial for CNS lymphoma, you will typically need to undergo additional diagnostic tests beyond those used for standard diagnosis. Clinical trials are research studies that test new treatments or treatment combinations. They have specific requirements, called eligibility criteria, that determine who can participate. These criteria help ensure the safety of participants and the reliability of the research results.

The diagnostic workup for clinical trial enrollment generally follows the same basic approach as standard diagnosis but may be more extensive or standardized. Researchers need detailed, consistent information about each participant’s disease to accurately evaluate whether new treatments are working. Most clinical trials for CNS lymphoma require confirmation of the diagnosis through tissue biopsy examined by a pathologist. The pathology report must clearly identify the type of lymphoma present.^[12]

Imaging studies are typically required at specific timepoints for clinical trial participants. Baseline MRI scans of the brain and spinal cord, performed before treatment begins, establish the size and location of tumors. These baseline images will be compared to scans taken later to determine whether the treatment is working. Trials often specify exactly how scans should be performed and may require that all scans be done at the same facility using the same type of equipment to ensure consistency.^[12]

Many clinical trials require examination of cerebrospinal fluid, even if cancer cells have already been found in brain tissue. This helps researchers understand the full extent of disease involvement in the nervous system. Some studies specifically look at whether treatments can eliminate cancer cells from the spinal fluid, so knowing whether these cells are present at the start of treatment is important.

Performance status assessment is a standard part of clinical trial screening. This evaluation measures how well you are able to carry out daily activities and how much your disease is affecting your functioning. Healthcare providers use standardized scales to rate performance status. Many trials only accept patients who are still relatively functional, though some trials specifically study treatments for patients whose disease has progressed further.

Blood tests for clinical trials are often more comprehensive than those for routine care. In addition to standard tests checking organ function and blood cell counts, trials may measure specific proteins, immune system markers, or genetic factors. Some studies collect extra blood samples for research purposes, such as looking for biomarkers that might predict how well a treatment will work or identifying patients who might benefit from targeted therapies.

⚠️ Important

Clinical trials may have age restrictions or requirements related to previous treatments. Some trials only accept patients who have never received treatment before, while others specifically study treatments for disease that has returned after prior therapy. Understanding these requirements before undergoing diagnostic testing for trial enrollment can help you and your healthcare team identify appropriate studies to consider.

Some clinical trials require molecular or genetic testing of tumor tissue. These tests look at the genetic makeup of cancer cells to identify specific mutations or other characteristics. For example, researchers know that most CNS lymphomas have specific genetic changes in pathways involved in cell growth and survival. Trials testing treatments that target these pathways may require proof that your tumor has the relevant genetic features. This type of testing is performed on the tissue obtained during biopsy.^[13]

Documentation requirements for clinical trials are more stringent than for routine care. All test results, pathology reports, imaging studies, and medical records must be carefully compiled and reviewed by the research team. You may need to sign consent forms allowing your medical information to be shared with trial investigators and regulatory authorities. The informed consent process for clinical trials includes detailed discussions about the purposes of all testing, potential risks and benefits, and your rights as a research participant.

If you are interested in clinical trials, discuss this with your healthcare team as early as possible in the diagnostic process. Some trials require that certain tests be performed within specific timeframes before treatment starts. Your doctor can help identify trials that might be appropriate for your situation and coordinate the necessary diagnostic evaluations. Organizations like the Lymphoma Research Foundation maintain databases of clinical trials for CNS lymphoma that you and your doctor can search together.^[5]

Prognosis and Survival Rate

Prognosis

The prognosis for central nervous system lymphoma has improved over recent decades, though it remains a serious diagnosis. If left untreated, primary CNS lymphoma is extremely aggressive, with survival measured in weeks to months. However, with appropriate treatment, many patients can achieve meaningful responses and periods of disease control.^[3]^[11]

Several factors influence how well a patient might do after diagnosis. Age plays a significant role—patients younger than 60 or 70 years old generally have better outcomes than older patients. The overall health and functional ability of the patient, called performance status, is another important factor. Patients who are still able to carry out most daily activities despite their illness tend to respond better to treatment than those who are more debilitated.^[13]

The location of tumors within the nervous system affects prognosis. Lymphomas located in certain brain regions, such as the areas deep within the brain including the periventricular regions, basal ganglia, brainstem, and cerebellum, are associated with poorer outcomes compared to tumors in the outer parts of the brain. Having tumors in both the brain and eyes at the same time is also linked to worse prognosis.^[13]

Laboratory findings provide additional prognostic information. Elevated levels of a substance called lactate dehydrogenase (LDH) in the blood or high protein levels in the cerebrospinal fluid suggest more aggressive disease. The presence of cancer cells in the cerebrospinal fluid, indicating spread throughout the nervous system, may also affect outcomes.^[13]

Immune status significantly impacts prognosis. Patients with HIV or AIDS or those taking immunosuppressant medications after organ transplant generally face greater treatment challenges. However, people who develop CNS lymphoma related to HIV may see improved outcomes if they receive highly active antiretroviral therapy to boost their immune system function.^[1]

About 30 percent of patients do not respond to initial treatment, and at least 50 percent of those who do respond will eventually experience disease relapse. The likelihood of long-term survival depends partly on how well the disease responds to first-line therapy and how long that response lasts. Patients whose disease comes back quickly after initial treatment generally have more limited options and poorer outcomes than those who remain in remission for longer periods.^[11]

Survival rate

Survival rates for CNS lymphoma vary considerably depending on treatment received, patient characteristics, and other factors. In published clinical trials, the median overall survival generally ranges from two to five years, meaning that half of patients live longer than this and half live for a shorter time.^[13]

Registry data, which captures outcomes for all patients rather than just those in clinical trials, shows a five-year survival rate of approximately 31 percent for all treated patients with primary CNS lymphoma. This means that about one in three patients survives for at least five years after diagnosis.^[11]

For younger patients who are healthy enough to receive intensive treatment, outcomes may be better. Those under age 70 who receive aggressive chemotherapy followed by additional consolidation treatment may achieve long-term survival more frequently than older or less healthy patients. Some studies report that intensive treatment approaches combining high-dose chemotherapy with stem cell transplantation can lead to prolonged remissions in select patients.^[11]

Historical survival data shows how much progress has been made in treating this disease. Without any treatment, median survival was only about 1.5 months. Early treatment approaches that relied mainly on radiation therapy improved survival but were associated with severe long-term side effects. Modern chemotherapy-based approaches have continued to improve outcomes while attempting to reduce toxicity.^[3]

It’s important to remember that survival statistics are based on groups of patients and cannot predict what will happen to any individual person. Each patient’s situation is unique, and many factors influence outcomes. Newer treatments and approaches continue to be developed and tested, offering hope for continued improvement in survival rates over time.

#1 Clinical Trials Search in Europe